Pre- and Post-Transcriptional Regulation of cFLIP for Effective Cancer Therapy Using pH-Ultrasensitive Nanoparticles

Cao Dai Phung1, Tuan Hiep Tran2,3, Ju-Yeon Choi1

  • 1College of Pharmacy, Yeungnam University, Gyeongsan 38541, Republic of Korea.

Insights

This study developed a novel nanoparticle to deliver cFLIP-specific siRNA and Vorinostat, effectively inhibiting cancer cell growth. The nanoparticle showed promising safety and efficacy in preclinical models for cancer therapy.

Area of Science:

  • Biomedical Engineering
  • Nanotechnology
  • Cancer Biology

Background:

  • Cellular FLIP (cFLIP) is overexpressed in solid cancers, driving apoptosis resistance.
  • Targeting cFLIP offers a therapeutic strategy for cancer treatment.
  • Developing effective delivery systems for cFLIP inhibitors is crucial.

Purpose of the Study:

  • To create a multifunctional nanoparticle for co-delivery of cFLIP-specific siRNA and Vorinostat.
  • To achieve pre- and post-transcriptional inhibition of cFLIP in cancer cells.
  • To enhance nanoparticle tumor targeting and cellular uptake in the acidic tumor microenvironment.

Main Methods:

  • Fabrication of mesoporous silica nanoparticles (MSN) loaded with Vorinostat (Vor).
  • Conjugation with polyethylenimine-biotin (PB) and electrostatic binding of cFLIP siRNA (siR).
  • PEGylation via Schiff base linkage for pH-sensitive deprotection and charge switching.

Main Results:

  • Successful synthesis of Vor/siR@MSN-PB-PEG nanoparticles with serum-stable siRNA.
  • Demonstrated post-transcriptional cFLIP downregulation by siRNA.
  • Achieved enhanced tumor accumulation and significant tumor inhibition due to targeted delivery and cFLIP suppression.

Conclusions:

  • The developed nanoparticle system effectively co-delivers siRNA and Vorinostat for synergistic cancer therapy.
  • pH-sensitive PEGylation enables targeted delivery and enhanced cellular internalization.
  • The combination regimen shows promising safety and efficacy for preclinical cancer treatment.